🇺🇸 FDA
Pipeline program

DS-8201a

D9673C00007

Approved small_molecule active

Quick answer

DS-8201a for Treatment of patients with HER2-positive breast cancer with or without brain metastasis is a Approved program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Treatment of patients with HER2-positive breast cancer with or without brain metastasis
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials